VAR - Galera Therapeutics Begins U.S. IPO Effort
Quick Take
Galera Therapeutics (GRTX) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing superoxide dismutase mimetics [SOD]-based therapeutics for complications resulting from cancer radiotherapy.
GRTX is preparing for Phase 3 trials for its lead candidate for the treatment of severe oral mucositis.
Company & Technology
Malvern, Pennsylvania-based Galera was founded in 2009 to develop SOD-based therapeutics for diseases resulting from cancer radiotherapy, such as severe oral mucositis [SOM].
Management is headed by President, CEO and Director J.